Despite rates of initial tumor cell dissemination to bone that appear similar regardless of ER status, clinically evident BMETs develop with twice the frequency in ER+ (vs. ER-) metastatic disease and remain concordant for ER+ expression in a majority of cases [9,10,11]. Here, ESR1 is linked to metastatic neoplasm.